Therapeutic discovery
Lysosomal Repair Modulators
Mechanism-guided exploration of compounds that may support lysosomal repair and cellular resilience.
ArcentLabs / Biotechnology R&D
Evidence-first
for life-science
R&D.
ArcentLabs is a computational biotech company. We build uncertainty-aware AI and in-silico models that prioritise hypotheses, candidates and protocols across preclinical and clinical development, so partners run fewer, better experiments and trials.
Explore our research Computational science
Experimental biology
Experimental biology
Deep-tech biotechnologyWhere computational insight
meets biological evidence.01 / 04
meets biological evidence.01 / 04
01Therapeutic discovery
02Bioprocess development
03Preclinical & clinical research
01 / Our focus
Science needs more than predictions. It needs evidence.
ArcentLabs develops uncertainty-aware computational systems for therapeutic discovery, bioprocess development and clinical research — helping scientists make better decisions before costly experiments, validation studies and trials.
01 Model the biology
02 Quantify uncertainty
03 Validate experimentally
02 / Research areas
Biology is
the brief.
Nine research directions across molecular discovery, computational biology, diagnostics, bioprocessing and clinical data science. Each is approached through testable hypotheses, explicit uncertainty and fit-for-purpose validation.
Ageing biology
Partial Epigenetic Reprogramming
A mechanistic New Approach Methodology (NAM) to investigate durable partial reprogramming in physiologically aged tissues.
Bioprocess development
AI for Cell-Culture Media & Processes
Data-efficient media formulation, feeding strategies and process-development workflows guided by AI.
Molecular diagnostics
Low-Cost Pathogen Sequencing
A direct-to-indexed modular backbone concept for streamlined and more accessible pathogen sequencing.
Clinical data science
Generative AI for Clinical Datasets
Methods to enhance clinical research datasets, with emphasis on data quality, utility and responsible validation.
Precision diagnostics
Deployable Biomarker Panels for IBD
Joint optimisation of predictive performance and practical assay deployment in inflammatory bowel disease.
Computational cell biology
Trustworthy Virtual-Cell Prediction
Calibrated perturbation-response prediction with uncertainty estimates and prospective experimental validation.
Translational screening
Human Intestinal Epithelium Screening
A computational workflow to prioritise compounds for functional testing in human intestinal epithelial models.
Immunotoxicology
Human TDAR Assay
T-cell-dependent antibody response (TDAR) assay approaches for immunosuppression screening.
Areas of investigation; not claims of therapeutic efficacy, regulatory approval or commercial readiness.
In-house experimental biology / Computational systems
03 / The research system
From in-silico
to in-vitro.
Our computational and laboratory capabilities support molecular discovery, cell-based validation and iterative development of early-stage therapeutic and biotechnology programs. Research is designed around experiments that can challenge a prediction, not merely confirm one.
04 / How we work
Rigour at every
decision point.
We combine computational precision with biological context — and design for the experiment that follows.
01 /
Biology first
Mechanism-led
Start with the biology and the decision to be made, rather than a preferred model architecture.
02 /
Intelligence
AI with context
Combine mechanistic reasoning, machine learning and carefully defined biological constraints.
03 /
Confidence
Uncertainty-aware
Make limitations visible through calibration, benchmarking and reproducible analysis.
04 /
Experiment
Validation-oriented
Prioritise testable hypotheses and follow computational insights with experimental evidence.
05 / About ArcentLabs
Computational intelligence.
Experimental biology.
ArcentLabs is a biotechnology company integrating proprietary generative, predictive and structural AI with in-house experimental biology.
Our computational and laboratory capabilities support molecular discovery, cell-based validation and iterative development of early-stage therapeutic and biotechnology programs.
Our work spans therapeutic discovery, bioprocess development, preclinical and clinical research. We focus on problems where experimental data are limited or heterogeneous, validation is expensive, and uncertainty must be made explicit rather than hidden.
Our research capabilities combine generative and predictive AI, structural modeling, molecular design, cell-based experimentation, microscopy, PCR and protein analysis. We apply these capabilities to develop computational platforms and early-stage biotechnology programs, including AI-guided therapeutic discovery.
Generative & predictive AIStructural biologyMolecular designMicroscopy & cell assaysPCR & protein analysisPreclinical & clinical research
06 / Collaboration
Let's move
the science
forward.
We welcome conversations with biotech companies, academic laboratories, clinical research teams and experimental partners working on ambitious biological questions.
partnership@arcentlabs.com ↗ArcentLabs OÜ
Tallinn, Estonia